Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
60 participants
OBSERVATIONAL
2019-06-01
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study, we will investigate the feasibility of enhanced UTE MR in human carotid arteries in vivo. Furthermore, we analyzed the correlation between UTE MR and microcalcification of in the carotid plaques. Based on the diagnostic ability of enhanced UTE MR for microcalcification, we will investigate the potential of enhanced calcification to distinguish symptomatic from asymptomatic patients with carotid atherosclerosis and research the prognostic ability of enhance calcufication in UTE MR.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Atherosclerotic Plaque Characterization
NCT00861653
Technical Innovation Protocol for MR & US Plaque Imaging: Reproducibility.
NCT01196221
Images in Extracranial Artery Stenosis
NCT00173927
Identification of Adverse Plaque Characteristics by Coronary MR Angiography
NCT01986868
Imaging Markers of High-Risk Plaque Phenotype for Predicting Post-PCI Outcomes
NCT07117084
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Calcification of atherosclerotic lesions was long thought to be an age - related, passive process where a combination of high local concentrations of phosphates and phosphatidylserines from necrotic cells and an absence of calcification inhibitors results in the precipitation of calcium phosphate particles. Recently increasingly data has revealed that atherosclerotic calcification is a more active process, involving complex signaling pathways and bone-like genetic programs. The distinction of early or active calcification as a destabilizing process and late calcification as a more stable state has also been supported by histological studies. This has lead to interest in characterizing early stages of calcification metabolically by making use of the positron emission tomography (PET)/CT imaging of atherosclerosis using 18F-sodium fluoride (18F-NaF), which has recently been reported having the potential to distinguish dormant areas with on-going mineralization and quiescent atherosclerotic calcium. Nevertheless, PET/CT is an expensive and a radioactive examination, which is not appropriate for large-scale screening or serial follow-up studies.
MRI is ideal for serial studies of lesions of atherosclerosis over time because it is noninvasive and is superior to other imaging modalities in distinguishing soft tissue contrast. In conventional gradient echo based MRI with TEs in the 1 to 2 ms range, however, the very short T2 relaxation time of solid calcifications on the order of some μs causes almost complete signal cancellation, which may cause significant overestimation of the calcified region and could not provide information about calcium density. Moreover, the low or zero signal from calcium with short T2 means that there is little opportunity to manipulate conspicuity by using different pulse sequences or contrast agents.
Recently, ultrashort echo time (UTE) MR, which allows detection of the ultrashort T2 components, has been used to image plaque calcification in ex vivo carotid and coronary arteries. The results demonstrated that UTE images are able to identify plaque calcification and enables accurate quantification of calcium volumes. However, gadolinium-based contrast agents during in vivo CMR could not be performed in these ex vivo study. Agnese et al. believed that calcifications with 18F-NaF PET uptake might be considered to represent dormant areas where on-going mineralization, which is a key sign to identify and localise ruptured and high risk coronary plaque. We, therefore, hypothesize that enhanced carotid calcification presented by UTE MR may be a critical sign for symptomatic patients.
In this study, we will investigate the feasibility of enhanced UTE MR in human carotid arteries in vivo. Furthermore, we analyzed the correlation between UTE MR and microcalcification of in the carotid plaques. Based on the diagnostic ability of enhanced UTE MR for microcalcification, we will investigate the potential of enhanced calcification to distinguish symptomatic from asymptomatic patients with carotid atherosclerosis and research the prognostic ability of enhance calcufication in UTE MR.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Asymptomatic group
Group with asymptomatic patients with carotid atherosclerosis.
MRI
Enhanced carotid calcification presented by UTE MR.
Symptomatic group
Group with symptomatic patients with carotid atherosclerosis.
MRI
Enhanced carotid calcification presented by UTE MR.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
MRI
Enhanced carotid calcification presented by UTE MR.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Li Min
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Li Min
Vice Director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Min Li
Jinan, Shandong, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
201703
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.